Systematic Surveillance Detects Multiple Silent Introductions and Household Transmission of Methicillin-Resistant Staphylococcus aureus USA300 in the East of England. by Toleman, Michelle S et al.
The Journal of Infectious Diseases
M A J O R A R T I C L E
Systematic Surveillance Detects Multiple Silent
Introductions and Household Transmission of Methicillin-
Resistant Staphylococcus aureus USA300 in the East of
England
Michelle S. Toleman,1,2,3 Sandra Reuter,1 Francesc Coll,1 Ewan M. Harrison,1 Beth Blane,1 Nicholas M. Brown,3,4 M. Estée Török,1,3,4 Julian Parkhill,2 and
Sharon J. Peacock1,2,3,5
1University of Cambridge, 2Wellcome Trust Sanger Institute, 3Cambridge University Hospitals NHS Foundation Trust, 4Clinical Microbiology and Public Health Laboratory, Public Health England,
Cambridge, and 5London School of Hygiene and Tropical Medicine, United Kingdom
Background. The spread of USA300 methicillin-resistant Staphylococcus aureus (MRSA) across the United States resulted in an
epidemic of infections. In Europe, only sporadic cases or small clusters of USA300 infections are described, and its prevalence in
England is unknown. We conducted prospective surveillance for USA300 in the east of England.
Methods. We undertook a 12-month prospective observational cohort study of all individuals with MRSA isolated from com-
munity and hospital samples submitted to a microbiology laboratory. At least 1 MRSA isolate from each individual underwent
whole-genome sequencing. USA300 was identiﬁed on the basis of sequence analysis, and phylogenetic comparisons were made be-
tween these and USA300 genomes from the United States.
Results. Between April 2012 and April 2013, we sequenced 2283 MRSA isolates (detected during carriage screening and in clin-
ical samples) from 1465 individuals. USA300 was isolated from 24 cases (1.6%). Ten cases (42%) had skin and soft tissue infection,
and 2 cases had invasive disease. Phylogenetic analyses identiﬁed multiple introductions and household transmission of USA300.
Conclusions. Use of a diagnostic laboratory as a sentinel for surveillance has identiﬁed repeated introductions of USA300 in
eastern England in 2012–2013, with evidence for limited transmission. Our results show how systematic surveillance could provide
an early warning of strain emergence and dissemination.
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Identiﬁcation of the community-associated methicillin-resistant
Staphylococcus aureus (CA-MRSA) pulsotype USA300 in the
United States in 1999 was followed by widespread dissemination
and an epidemic of MRSA infection in otherwise healthy people
[1, 2]. By 2004, this lineage was responsible for up to 97% of skin
and soft-tissue infections (SSTIs) among individuals presenting to
US emergency departments [3]. USA300 also causes invasive dis-
ease, such as pneumonia and osteomyelitis, and has become en-
demic in US hospitals, where it causes hospital-associated
infections, including bacteremia [4, 5]. USA300 is readily trans-
mitted within households, which act as long-term reservoirs
associated with repeated episodes of infection and onward
transmission [6, 7]. Antimicrobial resistance to macrolides and
ﬂuoroquinolones is common [3]. An epidemic of CA-MRSA
infection caused by a clone that is closely related to USA300
but arose independently (USA300 Latin American variant
[USA300-LV]) has also been identiﬁed in South America [8].
International travel is an important contributor to the inter-
continental spread of infectious diseases [9], and the spread of
USA300 and USA300-LV have been documented globally
[1, 10]. In theUnited Kingdom, the vastmajority ofMRSA infec-
tions continue to be caused by the dominant hospital-associated
lineage EMRSA-15 (ST22) [11]. USA300 is considered of
low prevalence in continental Europe, presenting primarily as
sporadic cases and in discrete, small outbreaks [12–18]. Simi-
larly, sporadic cases and a single hospital outbreak caused by
USA300 have been described in the United Kingdom [19–22],
but the prevalence of USA300 carriage and infection is unknown.
In the absence of systematic molecular surveillance of high-risk
lineages, we hypothesized that USA300 would only become ap-
parent in England if a high prevalence of SSTIs among patients
presenting to emergency departments triggered concern. Here,
we report the ﬁndings of systematic surveillance for USA300 in
a major diagnostic microbiology laboratory serving part of east-
ern England.
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METHODS
Study Design
A prospective study was conducted over 12 months between
April 2012 and April 2013 at the Public Health England Clinical
Microbiology and Public Health Laboratory, Cambridge Uni-
versity Hospitals NHS Foundation Trust in Cambridge, United
Kingdom. This laboratory processes samples submitted by 4
Cambridgeshire hospitals (Addenbrooke’s Hospital, the Rosie
Hospital, Papworth Hospital, and Hinchingbrooke Hospital)
and providers of community healthcare in the same geographic
region. We identiﬁed all cases with MRSA isolated at least once
from screening swabs and/or clinical specimens and collected
demographic and clinical data on MRSA-positive cases, using
electronic and paper medical records. Throughout the study pe-
riod, universal MRSA screening was performed at the 4 hospi-
tals, in accordance with national policy (multisite MRSA
screening of all patients on hospital admission and weekly
MRSA screening of patients in critical care units). The study
protocol was approved by the National Research Ethics Service
(reference 11/EE/0499), the National Information Governance
Board Ethics and Conﬁdentiality Committee (reference ECC
8-05(h)/2011), and the Cambridge University Hospitals NHS
Foundation Trust Research and Development Department (ref-
erence A092428).
Microbiologic Evaluation, DNA Sequencing, and Analysis
MRSA was isolated from screening samples by plating swabs
onto Brilliance MRSA chromogenic medium (Oxoid, Basing-
stoke, United Kingdom) and from all other samples by plating
onto Columbia Blood Agar (Oxoid, Basingstoke, United King-
dom). S. aureus was identiﬁed using a commercial latex agglu-
tination kit (Pastorex Staph Plus, Bio Rad Laboratories, Hemel
Hempstead, United Kingdom). Antimicrobial susceptibility was
determined to commonly used antibiotic agents (Figure 1),
using the VITEK 2 instrument (bioMerieux, Marcy l′Etoile,
France). Inducible clindamycin resistance was detected using
the D-test disk diffusion method. Antimicrobial susceptibility
results were interpreted using the European Committee on An-
timicrobial Susceptibility Testing criteria.
DNA was extracted, libraries prepared, and 150–base pair
paired-end sequences determined on an Illumina HiSeq2000
as previously described [23]. Multilocus sequence types
(MLSTs) were identiﬁed from the sequence data, using an in-
house script and the MLST database (available at: http://
saureus.mlst.net/), and assigned to clonal complexes (CCs).
CC8 isolates were identiﬁed and formed the basis for the re-
maining genetic analyses. CC8 were mapped using SMALT to
the S. aureus USA300 genome FPR3757 (GenBank accession
number CP000255.1). Mobile genetic elements, indels, and re-
gions of high-density single-nucleotide polymorphisms (SNPs)
were excluded. SNPs in this core genome were used to create
maximum likelihood phylogenies, using RAxML with 100
bootstraps [24]. Genome sequence data for 348 MRSA isolates
reported previously by Uhlemann et al were sourced from the
European Nucleotide Archive. Trees were visualized using Fig-
Tree (available at: http://tree.bio.ed.ac.uk/software/ﬁgtree/) and
iTOL [25]. Sequence data for the USA300 isolates from eastern
England have been submitted to the European Nucleotide Ar-
chive under the accession numbers listed in Supplementary
Table S1. In silico polymerase chain reaction analysis was
used to determine the staphylococcal cassette chromosome mec
(SCCmec) subtype [26]. To detect the presence of Panton-
Valentine leukocidin (PVL) genes (lukF-PV and lukS-PV),
the arginine catabolic mobile element (ACME), and the sta-
phylococcal pathogenicity island 5 (SAPI5), corresponding
sequences were extracted from the mapping alignment. Muta-
tions in the cap5 locus were retrieved from the assemblies by com-
parison to the cap5 locus of the CP5+ reference strain Newman
and USA300 reference strains TCH1516 and FPR3757, as de-
scribed previously [27]. The presence or absence of acquired
genes and SNPs conferring resistance against quinolones (grlA,
grlB, gyrA, and gyrB) were determined as described previously
[23]. For SNPs causing resistance in chromosomal genes, the stan-
dard mapping and SNP calling approach was used as described
earlier.
RESULTS
Description of Cases Positive for USA300
We identiﬁed 1465 individuals over a 12-month period with at
least 1 sample submitted to the microbiology laboratory at CUH
that was culture positive for MRSA, and we sequenced 2283 iso-
lates cultured from multisite screens or clinical samples from
these cases. CC8 isolates were identiﬁed and further evaluated
to identify USA300 (SCCmec type IVa, presence of PVL genes,
and phylogenetic clustering with USA300 reference genome
FPR3757; Figure 1A). This identiﬁed 56 USA300 isolates from
24 cases (Figure 1B), giving a case prevalence among MRSA car-
riers of 1.6% (24 of 1489). The majority of USA300-positive cases
were young (median, 32 years; range, 3–84 years; interquartile
range, 25–57 years), and males predominated (16 of 24 [67%]).
Over half of ﬁrst positive samples were submitted from ﬁrst-
opinion services (emergency departments, 8 of 24 [33%]; and
general practices, 5 of 24 [21%]), rather than from hospital inpa-
tient stays. Eleven cases had MRSA USA300 identiﬁed from car-
riage screening alone: 11 had MRSA USA300 collected from a
SSTI wound specimen, with or without associated carriage, and
1 each had invasive infection resulting in bloodstream infection
and osteomyelitis, respectively, with MRSA USA300 identiﬁed in
blood and bone samples, respectively (Figure 1B). Mapping the
residential address of the 24 cases demonstrated that 23 cases
were scattered across eastern England (Supplementary Figure S1),
while the remaining case was a US resident. Dates of collection of
the positive samples were distributed throughout the 12-month
study period, with a median time of 21 days (range, 0–332 days)
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between collection of the ﬁrst and last sequenced isolate (Supple-
mentary Table S1). The ﬁnding that MRSA USA300–positive
cases were distributed in time and space is suggestive of numerous
independent introduction events.
Genomic Investigation
The phylogenetic tree revealed 3 groups of closely related iso-
lates containing isolates from >1 individual (termed pairs/
clusters A, B, and C; Figure 1). Pair A contained 1 isolate each
from 2 cases (persons 11 and 12) that differed by 6 SNPs. Samples
were submitted 3 months apart from a general practitioner (ear
swab) and a hospital (multisite MRSA screen), and cases shared
the same registered address, suggesting household transmission.
Pair B contained 6 isolates from 2 cases (persons 17 and 18),
which differed by a median of 59 SNPs (range, 57–60 SNPs)
but differed from other isolates by a minimum of 81 SNPs.
These were isolated from samples collected within 2 weeks of
each other and submitted by a general practitioner (multisite
screen) and hospital (blood culture), respectively. The 2 cases
shared a surname but not address, which, given the larger number
of SNPs, potentially suggests spread between family contacts, rath-
er than household transmission. However, this must be interpret-
ed with caution. Cluster C contained 17 isolates from 3 cases
(persons 22, 23, and 24) with a median difference of 6 SNPs
(range, 0–9 SNPs) between isolates from different individuals.
Persons 22 and 24 had the same registered residential address
and had 16 MRSA isolates sequenced, the most closely related
of which were genetically identical. The single isolate from person
23 was also highly related (the closest genetic distances to isolates
from persons 22 and 24 were 1 and 7 SNPs, respectively), but no
direct or indirect epidemiological link between persons 22/24 and
person 23 could be identiﬁed. Overall, we found a maximum ge-
netic distance of 6, 59, and 9 SNPs among epidemiologically
linked cases. None of the cases had a recent history of hospitaliza-
tion in the same ward simultaneously (Supplementary Figure S2).
The 56 USA300 genomes from this study were combined with the
genomes of 348 MRSAUSA300 isolates fromNew York that have
been reported previously [6], to provide genetic context to the
United Kingdom isolates. A tree containing all isolates showed
that the United Kingdom study genomes were interspersed
throughout the tree (Figure 2), suggesting repeated introductions
of USA300 and ruling out a single importation and subsequent
propagation of a single clone. This picture of multiple introduc-
tions is similar to that reported in recent USA300 studies from
France and Switzerland [18, 28].
Figure 1. A, Phylogenetic, midpoint-rooted tree of study CC8 isolates, with USA300 isolates highlighted. A total of 56 isolates residing in the subclade within the gray box
were phylogenetically identified as USA300 isolates. B, Detailed USA300 phylogenetic tree rooted on the isolate from P01, with a summary of metadata for each isolate. Person
(P) numbers represent the study identifier of each individual from whom the sample was from, with gray boxes indicating pairs or clusters with presumptive epidemiological
links. ±Red, resistant; yellow, intermediate; blue, susceptible. *Ciprofloxacin: red, S80Y and S84L; blue, S80F only; white, none identified; gray, not done. Staphylococcal
cassette chromosome mec (SCCmec) IVa, Panton-Valentine leukocidin (PVL), arginine catabolic mobile element (ACME), staphylococcal pathogenicity island 5 (SAPI5): red,
present; black, absent. ^Red, 4 mutations associated with the CAP5 locus were identified. Abbreviation: SNP, single-nucleotide polymorphism.
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Variability in the USA300 Genome
We investigated the presence of mobile genetic elements pro-
posed previously to be associated with USA300 ﬁtness and ep-
idemic spread (Figure 1). Enterotoxins K and Q are thought to
enhance pathogenesis through T-cell stimulation and are en-
coded by sek2 and seq2 within a pathogenicity island, SAPI5
[29, 30]. SAPI5 was present in 25 of 56 isolates. The ACME
locus is a genomic island associated with USA300 that is com-
posed of at least 33 putative genes and 2 operons [31]. The arc
operon encodes genes involved in arginine catabolism, which
are important for survival of USA300 in acidic environments
[32]. ACME speG, which encodes a spermidine acetyltransfer-
ase, confers the ability to survive levels of the polyamines sper-
midine and spermine that are lethal for other strains of S. aureus
[33]. As described previously [6], ACME was variably present in
the USA300 isolates. Eight isolates from 3 cases were missing
this gene cassette. The dispersed position of ACME-negative
isolates in the phylogeny suggested multiple losses of the preex-
isting island. ACME-negative isolates did not carry the copper
and mercury resistance element, the presence of which would
be characteristic of South American strains of USA300-LV
[8]. Boyle-Vavra et al recently reported that USA300 failed to
produce capsular polysaccharide, which was associated with
the presence of 4 conserved mutations associated with the
cap5 locus when compared with strain Newman [27]. We con-
ﬁrmed that these 4 mutations were present in all of our 56
USA300 isolates. These cap5 mutations, together with SCCmec
IVa and PVL, therefore form a consistent marker of USA300 in
our collection, whereas ACME and SAPI5 are variably present.
Antimicrobial Resistance
The oral antibiotics used to treat MRSA SSTI in the United King-
dom and United States in single or combination regimens are
clindamycin, doxycycline and trimethoprim-sulfamethoxazole,
Figure 2. Comparison of the first USA300 isolate from each study case (n = 24, circles) relative to previously published USA300 isolates from the United States (n = 348) [6].
Mid-point rooted maximum likelihood tree based on single-nucleotide polymorphisms (SNPs) in the core genome of methicillin-resistant Staphylococcus aureus with branch
colors representing fluoroquinolone genotypes. Red branches: S80F/Y and S84A/L; yellow: S80F only; blue branches: nil; black branch: reference genome FPR3757. Letters
alongside circles indicate epidemiologically linked pairs or clusters.
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rifampicin, trimethoprim, and fusidic acid [34–36].All 56 isolates
were phenotypically susceptible to trimethoprim and clindamycin
(constitutive), and only 1 isolate tested resistant to tetracycline. Of
the 51 of 56 erythromycin-resistant isolates, none tested positive
for inducible clindamycin resistance. More than half of isolates
(36 of 56) were phenotypically resistant to ciproﬂoxacin and con-
tained known mutations in both grlA and gyrA (gyrA 84L and
grlA 80Y [n = 33] and grlA 80F alone [n = 3]). Previous studies
have reported that USA300 isolates from the United States segre-
gated into 2 clades based on ﬂuoroquinolone resistance genotypes
(with or without gyrA 84L/A and/or grlA 80Y/F mutations) [6, 7].
When the study isolates were considered in the context of the US
isolates (Figure 2), this was replicated for isolates from 22 cases,
the 2 exceptions being isolates from persons 7 and 13. Person 7
carried the 84L/80Y mutations and tested phenotypically resistant
but resided within the “susceptible” clade. Person 13 resided at the
base of the resistant clade and tested phenotypically resistant but
with an 80F mutation within grlA.
DISCUSSION
This study represents, to our knowledge, the ﬁrst prospective
surveillance study for USA300 in the United Kingdom. It pro-
vides clear evidence of how systematic whole-genome sequenc-
ing might assist in monitoring the distribution of a potentially
high-risk clone. Using whole-genome sequencing, we detected
multiple introductions of USA300 into eastern England. In
terms of epidemiological characteristics, most cases were
young and presented with SSTIs to ﬁrst-opinion services. This
is reminiscent of the early disease epidemiology of USA300 in
the United States, where this was largely associated with SSTIs
in the community before becoming introduced and established
through US hospitals [37]. Genomic studies have revealed re-
peated introductions of USA300 into American cities. The
source of the United Kingdom isolates is unknown, but it is like-
ly that international travel has played an important role; one
USA300 positive individual was normally resident in the United
States. Intercontinental transmission is supported by the similar
rates of resistance to oral antibiotics that are commonly used for
SSTIs caused by USA300, together with variability in the ge-
nome content reﬂecting the circulating strains in the United
States. We identiﬁed 2 likely independent acquisitions of cipro-
ﬂoxacin resistance in addition to those strains that represented
the ciproﬂoxacin-resistant clade that is seen in the United States
(Figure 1) [6, 7]. We found no evidence for the introduction of
USA300-LV from South America.
USA300 is known to have spread readily through communi-
ties in the United States, but we found limited evidence for such
transmission in our study. We identiﬁed 1 two-member pair
and 1 cluster of genetically closely related USA300. We found
epidemiological links between all but 1 individual within
these groups. Household transmission within pair A and cluster
C is supported by ﬁndings of previous US studies, in which a
median of 3 SNPs (range, 0–772 SNPs), 6 SNPs (range, 0–199
SNPs), and 5 SNPs (range, 0–102 SNPs) were identiﬁed per
household in New York, Los Angeles, and Chicago, respectively
[6, 7, 38].
Our prospective, systematic surveillance study found a prev-
alence rate of USA300 of 1.6%, which is >3 times higher than
the prevalence of MRSA isolates positive for mecC, a mecA ho-
molog associated with livestock [39]. Serial systematic preva-
lence studies for USA300 are lacking across Europe, but single
hospital studies from Switzerland have shown multiple impor-
tations and increasing rates [28], with 1 study showing an in-
crease in isolation rates from 0% to 9.2% between 2002 and
2012 [12]. Like continental European studies, United Kingdom
studies are sparse and strongly limited by surveillance methods
[10]. The potential for underascertainment within referral lab-
oratory–based infection surveillance studies is apparent when
comparing our report to another United Kingdom report; mo-
lecular testing in a reference laboratory study identiﬁed 40 likely
USA300 isolates (CC8 SCCmec IVa, spa t008, agr group 1, PVL
positive) from 300 CA-MRSA across England and Wales over a
2-year period (2004–2005) [40], yet we have identiﬁed 60% of
this total in 1 rather than 2 years and from a single region of
England.
The reasons underlying the rapid and widespread dissemina-
tion of USA300 in the United States remain unknown, despite
hypothesized roles for genetic elements such as ACME and,
more recently, the copB locus in raising ﬁtness [8, 32, 33]. Phy-
logenetic analysis has indicated a process of repeated introduc-
tion throughout the Americas prior to the epidemic [6, 7]. Our
data builds upon other European studies that suggest a similar
pattern in Europe, but without systematic surveillance it is dif-
ﬁcult to deﬁne the trajectory of USA300 in the United King-
dom. In contrast to when USA300 rapidly disseminated in
the United States >10 years ago, it is now feasible to implement
comprehensive, genomic surveillance strategies to monitor lin-
eage distribution and guide intervention. Had this been possible
during the initial stages of the US epidemic, alternative strate-
gies such as an aggressive targeted search-and-destroy policy
[41], may have been implemented. Currently, in Europe the ma-
jority of countries adopt a reactive rather than active manage-
ment strategy.
The current methods for surveillance of invasive staphylo-
coccal infections in the United Kingdom do not allow for the
monitoring of USA300. Antimicrobial susceptibility proﬁles
have been used as a surrogate marker of community lineages
on the basis of greater susceptibility overall, compared with
that for previous hospital-adapted lineages. This is prone to in-
creasing inaccuracy over time, since lineages may accumulate
drug resistance. For example, in the past, ciproﬂoxacin suscept-
ibility was used as a marker of United Kingdom community lin-
eages [42], but a substantial amount of resistance to this drug is
seen within USA300 (Figure 2). The molecular identiﬁcation of
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USA300 remains challenging since putative gene markers such
as the ACME element may be lost, and the 4 CAP5 mutations
recently described are also seen in the USA300 progenitor,
USA500 [27]. The use of whole-genome sequencing for the ge-
netic characterization of USA300 overcomes these barriers.
The national Staphylococcus Reference Unit at Public Health
England provides a reference service for microbiological charac-
terization of invasive S. aureus isolates, which includes spa typing,
toxin gene detection and whole-genome sequencing. However,
isolate submission is currently voluntary, highly selective, and
in practice tends to only be used to test isolates associated with
life-threatening infection [43]. Review of the local laboratory re-
cords showed that only 3 of 56 USA300 isolates were document-
ed as having been submitted to the national reference laboratory
and subsequently identiﬁed as consistent with potential USA300
strains.
We acknowledge a number of limitations in our study. Without
undertaking prevalence studies of all residents within a deﬁned
geographical area, studies are biased toward the healthcare-seek-
ing population. We tried to reduce this by including all disease
and carriage isolates over a yearlong period. Second, there is likely
to be United Kingdom–wide geographic variation in USA300 dis-
tribution. Third, ethical constraints mean that epidemiological
links between patients have been deduced using electronic medi-
cal records, which do not capture all epidemiological links. De-
spite these limitations, our study has identiﬁed the covert
presence of USA300 in eastern England. More broadly, it shows
that systematic whole-genome sequencing within a sentinel center
could function as an effective surveillance mechanism to monitor
MRSA lineages. If undertaken systematically, whole-genome se-
quencing–based sentinel surveillance within a coordinated net-
work could be used to provide an early warning of strain
emergence and dissemination; such epidemic intelligence would
allow appropriate targeting of resources toward interventions to
limit further spread.
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